SYGNATURE DISCOVERY
Live / Registered — Registered (as of 13 Jan 2026)
What this means for you
Registered since 13 Jan 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79410216
- Registration number
- 8097762
- Mark type
- Stylized text
- Filed
- 12 Sept 2024
- Published for opposition
- 25 Nov 2025
- Registered
- 13 Jan 2026
- Attorney of record
- Molly T. Eichten
Goods and services
- Class 001 — Chemicals: Proteins for industrial use; proteins for use in manufacture; proteins for use in scientific research; proteins for use in the manufacture of pharmaceutical products; protein in raw material form for material science, agritech, cosmeceutical research; protein in raw material form for industrial use; protein in raw material form for use in manufacture; protein in raw material form for use in scientific research; protein in raw material form for use in the manufacture of pharmaceutical products.
- Class 040 — Treatment of materials: Processing of organic chemical liquids in the nature of chemical distillery services; recycling of organic solvents; purification of proteins; purification of proteins by chemical methods.
- Class 042 — Scientific and technological services: Scientific research and development services; drug discovery services; development of pharmaceutical preparations and medicines; drug screening for scientific research purposes; pharmaceutical drug development services; research and development of vaccines and medicines; research and development of human and veterinary pharmaceutical drugs; research relating to medicines; services for assessing the efficacy of human and veterinary pharmaceutical drugs, namely, human and veterinary pharmaceutical product evaluation, human and veterinary pharmaceutical drug discovery services; conducting early evaluations in the field of new pharmaceuticals; consultancy in the field of pharmaceutical research; consultancy relating to pharmaceutical research and developments; development of pharmaceutical preparations and medicines; inspection of pharmaceuticals; laboratory research services relating to pharmaceuticals; pharmaceutical drug development services; pharmaceutical product evaluation; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and drug development; research and development in the pharmaceutical and drug development fields; testing of pharmaceutical drugs; assay development services being custom design and development of biophysical, biochemical, cell-based, phenotypic, in-vitro and in-vivo, assays; biological research; biological analysis; biological research laboratory services; biological research, clinical research in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases and medical research; consultancy relating to pharmacology; medical and pharmacological research services; scientific research for medical purposes in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases; research in the field of synthetic biology; research and development in the field of microorganisms and cells; chemical research and analysis services; chemical engineering; chemistry services, namely, laboratory research in the field of chemistry; medicinal, synthetic, analytical and high throughput chemistry services, namely, hit generation and optimization, lead optimisation, scale up manufacture, metabolite, analogue, impurity, and analytical standard synthesis and/or isolation and purification, structure elucidation; clinical research in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases; organic chemistry research and analysis services; consultancy in the field of organic chemistry; laboratory research and analysis services in the field of organic chemistry; research and development services in the field of organic chemistry; development, testing and analysis of chemicals; development, testing and analysis of chemical production methods; protein and peptide mapping for scientific purposes; scientific analysis services, namely, scientific analysis of materials for human and veterinary pharmaceutical, material science, agritech, cosmeceutical research for scientific research purposes; protein analysis services for scientific purposes; scientific research in the field of protein sequencing; protein crystallisation screening for scientific purposes; quality control for others; testing of materials; product testing; technological research in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases; industrial analysis and research services in the field of immunotherapy, cancerous diseases, respiratory diseases, neuroscience, fibrotic diseases, metabolic diseases and infectious diseases; scientific services relating to cell line generation; scientific screening services being ion channel screening, iterative screening, fragment screening and in silico screening, for scientific research purposes; compound profiling and selectivity services; X-ray and cryoelectronmicroscopy imaging and NMR structure determination of proteins, biological macromolecules and molecules, other than for medical purposes; blood analysis services for scientific research purposes; information, advisory and consultancy services relating to the aforesaid services.
Owner
Prosecution history
- 13 Jan 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 13 Jan 2026 — REGISTERED-PRINCIPAL REGISTER
- 25 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 25 Nov 2025 — PUBLISHED FOR OPPOSITION
- 19 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 24 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 24 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 24 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 09 May 2025 — REFUSAL PROCESSED BY IB
- 24 Apr 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 24 Apr 2025 — REFUSAL PROCESSED BY MPU
- 14 Mar 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 13 Mar 2025 — NON-FINAL ACTION WRITTEN
- 12 Mar 2025 — ASSIGNED TO EXAMINER